Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.
about
Getting in shape: controlling peptide bioactivity and bioavailability using conformational constraintsStructure-Guided Rational Design of α/β-Peptide Foldamers with High Affinity for BCL-2 Family Prosurvival ProteinsThe Melanocortin Receptor System: A Target for Multiple Degenerative DiseasesDesign of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challengeConformational study on cyclic melanocortin ligands and new insight into their binding mode at the MC4 receptor.On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffolds.Increasing αvβ3 selectivity of the anti-angiogenic drug cilengitide by N-methylation.Synthesis and screening of stereochemically diverse combinatorial libraries of peptide tertiary amides.Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients.Investigation of the novel lead of melanocortin 1 receptor for pigmentary disorders.Solid-phase synthesis of diverse peptide tertiary amides by reductive amination.Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation.Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors.Approaches to the rational design of selective melanocortin receptor antagonists.An unusual conformation of γ-melanocyte-stimulating hormone analogues leads to a selective human melanocortin 1 receptor antagonist for targeting melanoma cells.Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.N-methylation of peptides and proteins: an important element for modulating biological functions.Review backbone N-modified peptides: How to meet the challenge of secondary amine acylation.Novel approaches to the design of bioavailable melanotropins.Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment.Design of cyclic peptides with biological activities from biologically active peptides: the case of peptide modulators of melanocortin receptors.Design of cyclized selective melanotropins.Utilize conjugated melanotropins for the earlier diagnosis and treatment of melanomaNβ-methylation changes the recognition pattern of aza-β3-amino acid containing peptidomimetic substrates by protein kinase A.Incorporation of a bioactive reverse-turn heterocycle into a peptide template using solid-phase synthesis to probe melanocortin receptor selectivity and ligand conformations by 2D 1H NMR.Structural Insights into Selective Ligand-Receptor Interactions Leading to Receptor Inactivation Utilizing Selective Melanocortin 3 Receptor Antagonists.Melanocortin 1 Receptor Signaling Regulates Cholesterol Transport in Macrophages.Development of Novel Melanocortin Receptor Agonists Based on the Cyclic Peptide Framework of Sunflower Trypsin Inhibitor-1.Synthesis and in vitro bone cell activity of analogues of the cyclohexapeptide dianthin G.Development of Macrocyclic Peptidomimetics Containing Constrained α,α-Dialkylated Amino Acids with Potent and Selective Activity at Human Melanocortin Receptors.
P2860
Q27021652-8F77D67D-CBFA-416E-9602-33942F37C448Q27679468-FEA27DD0-2949-4C9C-AA44-9B0EA977B283Q28273671-B2FCACCE-96D3-4400-B4FB-1B3C9EF55C07Q33786376-0A9151F2-8E2F-4F44-AD55-345A1880C724Q33926210-9B9DFE78-0B79-4E67-BA66-8B4436067B19Q34030237-C2CE17AC-DDD4-4703-8550-80D3E23C9796Q34030885-B84CECBC-17A1-49B5-897E-6BD6372742C4Q34632423-17437B03-BAEB-446D-B2A1-A76EA7B19714Q34709012-78E2590D-4EF6-48E5-B96A-76F824CA4E7CQ35137889-8ADAEE5C-7E86-438E-8DAC-350FA10A2D3BQ35563845-D71D34E2-8B07-4B0C-8C12-0D555172C6EBQ35701298-34CCC2DF-0EAE-499F-8C36-D6F7E7A045BAQ36128120-60B7D0FB-94DF-46C1-8D22-1B8ADB82B43EQ36170873-34473301-41E7-4336-A7A5-24A5786B3EAEQ36809168-C0E7555E-35F4-412D-9775-E8DAAD107CC8Q37365405-B624F089-8DAC-4B4D-9FFD-6A71DE18A6ECQ38060675-EE83AE2E-1EA6-465A-A872-B33FFB762E6EQ38533393-4DDCFBC6-5045-43D6-88C2-4BDCF349A384Q38658728-F904DC4A-8378-45A8-A8EE-179B22D3D596Q38767147-9498D014-7BA1-4738-BAB8-E8E30826E71BQ38917039-03545629-0E72-408A-9342-1C5BE8C5A890Q38937114-3BE350B3-BCC1-4877-BA91-0938E5A589C8Q39593902-29AF5A31-5EA4-494F-B1B1-1C84C7F48576Q42579098-5BF637D6-8265-4C04-B770-E64893D6A014Q42660235-352609BB-3539-4FBE-9B61-1016B3FA4679Q45063479-9F4DE865-7D29-441B-95FA-A80E99B5C81DQ51031177-8AA2BBA5-4310-442F-8CE8-EDFD71B932DEQ52615555-28CF53CF-AEE9-492F-942E-3C3C8F489C9CQ53155600-A9135F7E-EB2F-458F-94B3-8397F469A90DQ55421852-6A398F02-8288-42E8-8AF2-5FDAB848B451
P2860
Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Multiple N-methylation of MT-I ...... al and conformational studies.
@ast
Multiple N-methylation of MT-I ...... al and conformational studies.
@en
Multiple N-methylation of MT-I ...... al and conformational studies.
@nl
type
label
Multiple N-methylation of MT-I ...... al and conformational studies.
@ast
Multiple N-methylation of MT-I ...... al and conformational studies.
@en
Multiple N-methylation of MT-I ...... al and conformational studies.
@nl
prefLabel
Multiple N-methylation of MT-I ...... al and conformational studies.
@ast
Multiple N-methylation of MT-I ...... al and conformational studies.
@en
Multiple N-methylation of MT-I ...... al and conformational studies.
@nl
P2093
P2860
P356
P1476
Multiple N-methylation of MT-I ...... al and conformational studies.
@en
P2093
Erin Palmer
Florian Opperer
Horst Kessler
Johannes G Beck
Lucas Doedens
Matt Dedek
Minying Cai
Victor J Hruby
P2860
P304
P356
10.1021/JA101428M
P407
P577
2010-06-01T00:00:00Z